Phaseline

Targets › ERCC3

ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.

ATP-dependent 3'-5' DNA helicase/translocase. Binds dsDNA rather than ssDNA, unzipping it in a translocase rather than classical helicase activity. (UniProt, P19447)

Open in Phaseline: the race on ERCC3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
M.D. Anderson Cancer CenterTrabectedin
Alkylating agent - binds DNA and inhibits transcription, particularly affecting transcript
ERCC2, ERCC3Phase 2Uterine Leiomyosarcoma; Soft Tissue SarcomasDec 2027

Conditions

Uterine Leiomyosarcoma (1) Soft Tissue Sarcomas (1)

Modalities

mixed (1)

Companies

M.D. Anderson Cancer Center (1)

Related targets

ERCC2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.